ArticleTranslational andrology and urology2024
Changes in complement C3a in the immunotherapy of advanced clear cell renal cell carcinoma.
Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MUC1/CA15-3 identifies a clear cell renal carcinoma characterized by Sunitinib response with a specific metabolic signature.Clinical and experimental medicine · 2026Article
- Targeting the complement system: notes on therapeutic strategies for renal cancer.Future medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy is an emerging treatment modality for clear cell renal cell carcinoma (CCRCC). As a molecule involved in the prognosis of CCRCC, the effect of complement C3a expression levels on immunotherapy is unclear. This study aims to investigate the correlation between C3a and clinicopathological features in early CCRCC, as well as the alterations in complement C3a during immunotherapy for advanced CCRCC and its influence on therapeutic outcomes. Methods: Immunohistochemistry was used to detect the expression of complement C3a in newly diagnosed CCRCC tissues and paracancerous tissues. The peripheral serum of advanced CCRCC patients who underwent programmed cell death protein 1 (PD-1) antibody immunotherapy was collected before treatment and after four cycles of treatment, and detected by enzyme-linked immunosorbent assay. For the concentration of complement C3a, the Response Evaluation Criteria in Solid Tumors version 1.1 was used to evaluate the therapeutic effect. Results: Of the 110 CCRCC cases, 76 (69.09%) were positive for C3a expression, showing brown staining in the cytoplasm and membrane of the tumor cells. No difference was observed in the expression of complement C3a in the tumor tissues in terms of gender, age, location, and histological grade. The expression of complement C3a in tumors with a maximum transverse diameter >3.5 cm was higher than that in tumors with a maximum transverse diameter ≤3.5 cm (P=0.02), and the expression of complement C3a in the tissues of the tumor node metastasis classification (TNM) stage II patients was higher than that of the TNM stage I patients (P=0.005). Among the 30 patients with advanced CCRCC who underwent immunotherapy, 12 had a complete response (CR) or a partial response (PR), 7 had stable disease (SD), and 11 had progressive disease (PD). The C3a concentration decreased in the CR + PR + SD group after treatment, while it increased in the PD group and the difference was statistically significant. The survival analysis indicated that the progression-free survival of patients with decreased complement C3a after treatment was longer than that of patients with increased C3a (P<0.001). Conclusions: Complement C3a is highly expressed in CCRCC, and the high expression of complement C3a is related to the stage and tumor size. During immunotherapy for CCRCC, changes in complement C3a can reflect the curative effect to a certain extent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.